ISA 101

Drug Profile

ISA 101

Alternative Names: HPV-SLP; HPV16-SLP; Human papilloma virus type 16 E6/E7 synthetic long peptides - ISA Pharmaceuticals; ISA-01; ISA-HPV; ISA-HPV-01; ISA-HPV-SLP®; ISA101; SLP-HPV-01

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator ISA Pharmaceuticals
  • Developer Bristol-Myers Squibb; ISA Pharmaceuticals; Shin Nippon Biomedical Laboratories; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Papillomavirus vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vulvar intraepithelial neoplasia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Solid tumours; Vulvar intraepithelial neoplasia
  • Phase I/II Anal intraepithelial neoplasia

Most Recent Events

  • 07 Dec 2015 Phase-II clinical trials in Solid tumours (Combination therapy) in USA (SC)
  • 13 Aug 2015 Phase-II clinical trials in Cervical cancer (Combination therapy) in Belgium and Netherlands (SC)
  • 24 Jun 2015 ISA Pharmaceuticals receives patent allowance for HPV antigen-based peptides in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top